MediWound Shares Fall on Cut to 2025 Revenue Outlook

Dow Jones

Jan 12

By Elias Schisgall

MediWound shares fell after the company cut its outlook for 2025 revenue, citing the U.S. government shutdown as weighing on revenue in the fourth quarter.

Shares fell 6.3% to $17.53 in Monday morning trading. The stock is down 4.2% over the past year.

The Israeli biopharmaceutical company said Monday it expects to report $17 million in 2025 revenue. It had previously guided for $24 million in revenue for the year in May.

The company said it expects revenue to grow to between $24 million and $26 million in 2026, rising to between $32 million and $35 million in 2027 and between $50 million and $55 million in 2028.

"While U.S. government shutdown--related delays impacted revenue recognition in our fourth quarter results, and certain activities are still pending, we believe these effects are timing-related, and that we now have the key elements in place to continue executing our strategy, as reflected in our revised three-year revenue guidance," Chief Executive Officer Ofer Gonen said.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 12, 2026 10:47 ET (15:47 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602544817"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602544817\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602544817?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 23:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602544817","market":"other","top_or_hot":-1,"title":"MediWound Shares Fall on Cut to 2025 Revenue Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MediWound shares fell after the company cut its outlook for 2025 revenue, citing the U.S. government shutdown as weighing on revenue in the fourth quarter. \n</p>\n<p>\n  Shares fell 6.3% to $17.53 in Monday morning trading. The stock is down 4.2% over the past year. \n</p>\n<p>\n  The Israeli biopharmaceutical company said Monday it expects to report $17 million in 2025 revenue. It had previously guided for $24 million in revenue for the year in May. \n</p>\n<p>\n  The company said it expects revenue to grow to between $24 million and $26 million in 2026, rising to between $32 million and $35 million in 2027 and between $50 million and $55 million in 2028. \n</p>\n<p>\n  \"While U.S. government shutdown--related delays impacted revenue recognition in our fourth quarter results, and certain activities are still pending, we believe these effects are timing-related, and that we now have the key elements in place to continue executing our strategy, as reflected in our revised three-year revenue guidance,\" Chief Executive Officer Ofer Gonen said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 10:47 ET (15:47 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MediWound Shares Fall on Cut to 2025 Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMediWound Shares Fall on Cut to 2025 Revenue Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-12 23:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MediWound shares fell after the company cut its outlook for 2025 revenue, citing the U.S. government shutdown as weighing on revenue in the fourth quarter. \n</p>\n<p>\n  Shares fell 6.3% to $17.53 in Monday morning trading. The stock is down 4.2% over the past year. \n</p>\n<p>\n  The Israeli biopharmaceutical company said Monday it expects to report $17 million in 2025 revenue. It had previously guided for $24 million in revenue for the year in May. \n</p>\n<p>\n  The company said it expects revenue to grow to between $24 million and $26 million in 2026, rising to between $32 million and $35 million in 2027 and between $50 million and $55 million in 2028. \n</p>\n<p>\n  \"While U.S. government shutdown--related delays impacted revenue recognition in our fourth quarter results, and certain activities are still pending, we believe these effects are timing-related, and that we now have the key elements in place to continue executing our strategy, as reflected in our revised three-year revenue guidance,\" Chief Executive Officer Ofer Gonen said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 10:47 ET (15:47 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDWD","symbol_name":"MediWound Ltd.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602544817","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602544817","pubTimestamp":1768232820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MediWound shares fell after the company cut its outlook for 2025 revenue, citing the U.S. government shutdown as weighing on revenue in the fourth quarter.Shares fell 6.3% to $17.53 in Monday morning trading. The stock is down 4.2% over the past year.The Israeli biopharmaceutical company said Monday it expects to report $17 million in 2025 revenue. It had previously guided for $24 million in revenue for the year in May.The company said it expects revenue to grow to between $24 million and $26 million in 2026, rising to between $32 million and $35 million in 2027 and between $50 million and $55 million in 2028.\"While U.S. government shutdown--related delays impacted revenue recognition in our fourth quarter results, and certain activities are still pending, we believe these effects are timing-related, and that we now have the key elements in place to continue executing our strategy, as reflected in our revised three-year revenue guidance,\" Chief Executive Officer Ofer Gonen said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MDWD":"MediWound Ltd."},"translate_title":"MediWound股价因2025年收入前景下调而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDWD":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  MediWound shares fell after the company cut its outlook for 2025 revenue, citing the U.S. government shutdown as weighing on revenue in the fourth quarter. \n\n\n  Shares fell 6.3% to $17.53 in Monday morning trading. The stock is down 4.2% over the past year. \n\n\n  The Israeli biopharmaceutical company said Monday it expects to report $17 million in 2025 revenue. It had previously guided for $24 million in revenue for the year in May. \n\n\n  The company said it expects revenue to grow to between $24 million and $26 million in 2026, rising to between $32 million and $35 million in 2027 and between $50 million and $55 million in 2028. \n\n\n  \"While U.S. government shutdown--related delays impacted revenue recognition in our fourth quarter results, and certain activities are still pending, we believe these effects are timing-related, and that we now have the key elements in place to continue executing our strategy, as reflected in our revised three-year revenue guidance,\" Chief Executive Officer Ofer Gonen said. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 10:47 ET (15:47 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}